Skip to main content
Caplight Logo









AIRNA

AIRNA

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://airna.com/

Last Round

Series B

Apr 1, 2025

Total Funding Raised

$305M

Company Overview

AIRNA is a biotechnology company that develops RNA-editing therapeutics to treat rare and common diseases by leveraging its proprietary RESTORE+™ platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

RNA editingtherapeutic pipelineAlpha-1 Antitrypsin DeficiencyAATDgenetic medicineoligonucleotide therapeuticsclinical-stage biotechgene editingRNA therapeuticsbiotech startupdrug developmentcardiometabolic diseasetherapeutic platformbiotech licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AIRNA Comparables

Compare AIRNA with similar companies based on industry and business-model similarity.

AIRNA comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Frequency Therapeutics
91%
Wave Life Sciences
87%
Ascidian Therapeutics
81%

AIRNA Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BApr 1, 2025
Series A ExtensionJul 31, 2024
Series ASep 19, 2023

Key People

Founding team and executive leadership

Todd Bazemore

Chief Executive Officer

Executive Team

AIRNA Investors

Notable investors and investment history

AIRNA investors
InvestorRounds
LifeLink VenturesSeries B
Codon CapitalSeries A
ForbionSeries B, Series A, Series A Extension
ARCH Venture PartnersSeries B, Series A Extension, Series A
+ND CapitalSeries B, Series A, Series A Extension
ARCH Venture PartnersSeries B, Series A Extension, Series A
Alexandria Venture InvestmentsSeries A, Series A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors increased 82% MoM.

  • Apr 22, 2026

    Developing new medicines for rare and common diseases, starting with AATD.

AIRNA Filings

Explore SEC and related filing metadata, where available.

AIRNA filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about AIRNA's valuation, stock price, and market status.

Is AIRNA a public or private company?

AIRNA is a private company.

What is the current stock price of AIRNA?

AIRNA is a private company with no public stock price. No recent secondary market data is available.

How much is AIRNA worth (valuation)?

Valuation information for AIRNA is not publicly available.

Can I buy AIRNA stock?

AIRNA shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was AIRNA's last funding round?

AIRNA's most recent funding round was Series B on April 1, 2025.

Who are the main investors in AIRNA?

Key investors in AIRNA include ARCH Venture Partners, Venrock.

Will AIRNA IPO soon?

No public IPO plans have been announced for AIRNA.

How can I track AIRNA secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor AIRNA's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range59
Year Founded2021
Last FundingApr 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?